Ask sales for the Certificate of Analysis matched to the offered or supplied lot; it records the tests actually completed, applicable specifications, and reported results.

Matching batch COA available.

FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →

FDA PCAC: 7 peptides under review. Read →

Kisspeptin-10

Name: Kisspeptin-10
Brand: Vialdyne
SKU: kisspeptin-10

Metastin (45-54) · HPG-axis research peptide

≥ 99.0%CAS 374675-21-5GH-Axis Peptides

Overview

Kisspeptin-10 (KP-10) is a member of the neuropeptide family encoded by the KISS1 gene — the 10-amino-acid active C-terminal fragment of the 145-amino-acid kisspeptin precursor protein, also known as Metastin (45-54). Regarded as a "master regulator" of the reproductive system, KP-10 is the endogenous ligand for hypothalamic GnRH neurons and is essential for the onset of puberty, fertility, and reproductive function. Current research is exploring its therapeutic potential in infertility, low sexual desire, and reproductive disorders. Vialdyne releases Kisspeptin-10 as a lyophilized decapeptide (linear) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.

Applications & buyer fit

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

How Kisspeptin-10 is sourced

Sourced for

503A / 503B compounding dispensed under physician supervision
Research into somatotropic-axis pharmacology

Buyer fit

academic and contract research laboratories

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Counter-ion (acetate vs TFA)
Sterile-fill release pack (sterility, CCI, fill-weight)
Bacterial endotoxin (LAL, USP <85>)
Stability data on request
SDS / MSDS

Procurement note: For sterile-filled vials, confirm whether sterility, endotoxin, and CCI are included in the agreed release packet. For loose lyophilized powder, request the batch COA and separately scope any sequence-level evidence required by the buyer's written procedure.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS: 374675-21-5
Molecular Formula: C63H83N17O14
Molecular Weight: 1302.45 g/mol
Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
Appearance: White, fluffy lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 5 mg – 10 mg
Packaging: 10 vials/box · base pack (multiples of 10)
Half-life: ≈ 4 minutes
MOQ: On request
Lead time: 10–18 days
Storage: -20°C, protect from light

Certificate of Analysis

Representative COA previews for Kisspeptin-10; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Kisspeptin-10

VD260428-KS10118 · 99.36%

VerifiedRequest full COA →

Kisspeptin-10

VD260428-KS5117 · 99.59%

Browse all published COAs

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627.
de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003;100(19):10972-10976.
George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, Anderson RA. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-E1236.
Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. J Clin Endocrinol Metab. 2014;99(6):E953-E961.
Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677.
Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719.

Frequently asked questions

What release specifications and COA parameters should a qualification file for Kisspeptin-10 API include?▾

A defensible qualification packet lists identity by mass spectrometry against the theoretical mass of the C-terminal decapeptide, purity by RP-HPLC with an area-percent acceptance limit, and confirmation of the intact RFamide C-terminus since that motif governs GPR54 binding. Because Kisspeptin-10 is produced by solid-phase synthesis rather than fragment processing, the impurity profile is dominated by synthesis-related species, so the COA should report a related-substances profile alongside net peptide content, counterion identity, water content, and residual solvents. Endotoxin and microbial limits complete the release file for a compounding-oriented buyer.

How should Kisspeptin-10 be stored and reconstituted to preserve the assayed potency stated on the COA?▾

The lyophilized solid is the stable form and should be held desiccated and cold, with the sealed vial equilibrated to room temperature before opening to prevent condensation onto hygroscopic powder. The net-peptide value on the certificate, not gross vial weight, is the correct basis for calculating reconstitution volume. In solution the decapeptide is far less stable than in the solid state, so working aliquots should be prepared and either used promptly or frozen once, avoiding repeated freeze-thaw. Documenting reconstitution diluent, concentration, and date supports traceability back to the released batch.

Kisspeptin-10

Metastin (45-54) · HPG-axis research peptide

≥ 99.0%CAS 374675-21-5GH-Axis Peptides

Overview

Applications & buyer fit

How Kisspeptin-10 is sourced

Sourced for

503A / 503B compounding dispensed under physician supervision
Research into somatotropic-axis pharmacology

Buyer fit

academic and contract research laboratories

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Counter-ion (acetate vs TFA)
Sterile-fill release pack (sterility, CCI, fill-weight)
Bacterial endotoxin (LAL, USP <85>)
Stability data on request
SDS / MSDS

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS: 374675-21-5
Molecular Formula: C63H83N17O14
Molecular Weight: 1302.45 g/mol
Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
Appearance: White, fluffy lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 5 mg – 10 mg
Packaging: 10 vials/box · base pack (multiples of 10)
Half-life: ≈ 4 minutes
MOQ: On request
Lead time: 10–18 days
Storage: -20°C, protect from light

Certificate of Analysis

VerifiedRequest full COA →

Kisspeptin-10

VD260428-KS10118 · 99.36%

VerifiedRequest full COA →

Kisspeptin-10

VD260428-KS5117 · 99.59%

Browse all published COAs

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627.
de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003;100(19):10972-10976.
George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, Anderson RA. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-E1236.
Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. J Clin Endocrinol Metab. 2014;99(6):E953-E961.
Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677.
Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719.

Frequently asked questions

What release specifications and COA parameters should a qualification file for Kisspeptin-10 API include?▾

How should Kisspeptin-10 be stored and reconstituted to preserve the assayed potency stated on the COA?▾